Press Releases Events & Presentations Event Details European Association for the Study of the Liver (EASL) Congress 2025 May 7 - May 10, 2025 Supporting Materials ABI-6250 - Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D 943.6 KB ABI-4334 - Sustained inhibition of HBV replication and HBsAg levels after long-term treatment with CAM ABI-4334 in human hepatocytes 2.2 MB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
European Association for the Study of the Liver (EASL) Congress 2025 May 7 - May 10, 2025 Supporting Materials ABI-6250 - Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D 943.6 KB ABI-4334 - Sustained inhibition of HBV replication and HBsAg levels after long-term treatment with CAM ABI-4334 in human hepatocytes 2.2 MB
ABI-6250 - Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D 943.6 KB
ABI-4334 - Sustained inhibition of HBV replication and HBsAg levels after long-term treatment with CAM ABI-4334 in human hepatocytes 2.2 MB
